BIO 2025 Report: U.S. Bioscience Industry Policy Guide for State Growth

Key Takeaways

• States are adopting phase-specific policy approaches tailored to company development stage, from discovery and seed through commercialization and maturity.
• Financial tools—including R&D tax credits, grant matching programs, angel investor credits, and biomanufacturing incentives—reduce capital barriers for startups and growth-stage firms.
• Workforce initiatives, university-industry collaborations, and government partnerships form the foundation of sustainable bioscience ecosystems.
• Venture capital investment in biopharma rebounded in 2024 to $26 billion, up from $23.3 billion in 2023, signaling renewed confidence in the sector.
• Public bioscience company revenue grew 6.8% year-over-year in 2024 to $205 billion, demonstrating continued commercial strength.

What Policy Tools Drive State Bioscience Growth?

The report identifies matched funding mechanisms as central to reducing financial barriers across development stages. At the discovery and seed stage, states deploy grant-matching programs that amplify federal SBIR and STTR awards, subsidized incubators, and proof-of-concept funds. During early-stage venture capital phases, state venture capital programs operate as "fund-of-funds," attracting professional investment management while ensuring capital flows to local companies. Growth-stage firms benefit from economic development incentives, tax abatements for facility expansion, and infrastructure investment in specialized bio-parks. The framework emphasizes that one-size-fits-all approaches are less effective than ecosystem strategies calibrated to company phase and regional needs.

Why Workforce Development and Collaboration Matter

The report underscores that bioscience success depends on continuous talent pipelines and interconnected partnerships. State workforce initiatives—spanning K-12 STEM education, community college certificates, and university-industry collaborations—align curricula with industry demands for laboratory technicians, clinical research associates, and biomanufacturing specialists. Public-private partnerships between universities, government agencies such as the National Institutes of Health, and private companies accelerate translation of foundational research into commercially viable products. Inter-company alliances between established pharmaceutical firms and emerging biotech companies combine scale with agility, reducing development risk and fostering knowledge exchange.

Frequently Asked Questions

Who published this report and what is its scope?

The report was published in December 2025 by the Biotechnology Innovation Organization (BIO) in partnership with the Council of State Bioscience Associations (CSBA). It is the seventh edition of BIO's state and regional economic development guide, designed to assist policy leaders and industry partners in identifying measures that enhance bioscience industry prospects in their states and regions.

How should pharmaceutical and biotech leaders use this guide?

For biopharma executives, the report serves as a practical scan of state-level policy landscapes relevant to site selection, R&D expansion, clinical development planning, and manufacturing scale-up. Public affairs, business development, and regulatory teams can use the phase-specific framework to identify incentives, workforce programs, and partnership opportunities aligned with their company's development stage and growth strategy.

What economic data supports the bioscience sector's importance?

According to the report, the U.S. bioscience industry's total economic output exceeded $3.2 trillion in 2023. Venture capital investment in biopharma rebounded to $26 billion in 2024, up from $23.3 billion in 2023. Public bioscience company revenue grew 6.8% year-over-year in 2024 to $205 billion. The report cites Investopedia data projecting the bioscience product market to grow from $1.7 trillion in 2025 to over $5 trillion by 2034, representing an annual growth rate of 12.5%.

What is the next step for states looking to implement these strategies?

The 2026 State and Regional Policy Guide recommends that states assess their current bioscience ecosystem and identify which development stages—discovery and seed, early stage, growth and expansion, or maturity and commercialization—require the most support. States should then tailor incentive programs, workforce initiatives, and public-private partnerships to address bottlenecks specific to their regional industry profile and competitive position.